Buy & Sell Regeneron Pharmaceuticals Inc (REGN) – Regeneron Pharmaceuticals Inc Price Today
Aura AI Summary
Key Stats
- $73.63BMarket Cap
- HealthSector
- -14.52%3M Drawdown
- $67.58BEnterprise Value
- 0.54%Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 96 daysTypical Hold Time
Regeneron Pharmaceuticals Inc (REGN) is currently valued at a market capitalization of $73.63B, with an enterprise value of $67.58B. Over the past 52 weeks, Regeneron Pharmaceuticals Inc has traded between a low of $483.07 and a high of $812.27, highlighting its annual price range. Over the past three months, Regeneron Pharmaceuticals Inc has recorded a drawdown of -14.52%, reflecting recent price volatility. Regeneron Pharmaceuticals Inc offers a dividend yield of 0.54%, with the most recent dividend of $0.94 paid on 20 Feb 26. On average, investors hold Regeneron Pharmaceuticals Inc for approximately 96 days, indicating typical investor behavior on the platform.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Most Recent News
Axon beats Q1 earnings and revenue estimates but shares fall 2.8% in after-hours trading
Axon Enterprise reported Q1 earnings of $1.61 per share, slightly above the $1.60 estimate, and revenue of $807.35 million, beating the $778.45 million forecast. Key growth drivers included a 35% rise in Software & Services revenue, over 700% growth ...
Snap beats Q1 earnings estimates with user growth and revenue gains, but shares fall in after-hours trading.
Snap Inc. reported better-than-expected Q1 results, with a loss of five cents per share beating the estimated seven cents loss, and revenue of $1.529 billion slightly above forecasts. The company saw a 5% year-over-year increase in both global monthl...
Robinhood opens private market fund to 150,000 retail investors with daily liquidity and no accreditation needed.
Robinhood has launched its Ventures Fund I, a publicly traded closed-end fund on the NYSE, allowing 150,000 retail investors access to private companies like OpenAI and Stripe without accreditation requirements. The fund offers daily liquidity and ch...
